Listing & Compliance Notices

Expion360 Inc. received a nasdaq compliance regained notice regarding late filing (rules 5550(b)(1)).

“August 20, 2025, the Company received a notification letter (the “ Notice ”) from the Nasdaq Listing Qualifications department of The Nasdaq Stock Market (“ Nasdaq ”) notifying the Company that the stockholders’ equity balance reported in the Q2 Quarterly Report was below the $2.5 million required minimum for continued listing on the Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the “ Equity Rule ”). The Notice also provided that the Company has 45 calendar days to submit a plan to regain compliance. However, the Company believes that, as a result of the positive impact”

Bayview Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“August 22, 2025, Bayview Acquisition Corp, a Cayman Island exempted corporation (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company is not in compliance with Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Rule”), which requires the Company to maintain a minimum Market Value of Listed Securities (“MVLS”) of $50.0 million. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the C”

XCF Global, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“August 21, 2025, XCF Global, Inc. (the “Company”) was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was no longer compliant with Nasdaq rule 5250(c)(1) due to the delay in filing the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “Q2 Form 10-Q”). Under Nasdaq rules, XCF has 60 calendar days, or until October 20, 2025, to submit a plan to regain compliance. If XCF’s plan is accepted, Nasdaq can grant an exception of up to 180 calendar days from the due date of the Q2 Form 10-Q, or until February 17, 2026, to regain compliance. The notice ha”

QUANTUM CORP /DE/ received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“August 21, 2025, Quantum Corporation (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025 (the “Quarterly Report”) with the Securities and Exchange Commission (the “SEC”). On August 15, 2025, the Company filed a Notification of Late Filing on Form 12b-25 with the SEC indicating that the Quarterly Report”

PETMED EXPRESS INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“August 20, 2025, PetMed Express, Inc. (the “ Company ”) received a notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), which indicated that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for its fiscal year ended March 31, 2025 (the “ Annual Report ”) and its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “ Quarterly Report ”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “ Listing Rule ”), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the U.”

ACTELIS NETWORKS INC received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1), 5815(d)(4)(B)).

“August 19, 2025, Actelis Networks, Inc. (the “Company”) received written notice from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that, due to the Company’s non-compliance with the $2.5 million stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”) as of June 30, 2025, and because, pursuant to Listing Rule 5815(d)(4)(B), the Company remained subject to a mandatory hearing panel monitor through August 27, 2025, the Company’s securities were subject to delisting from Nasdaq unless the Company timely request”

BATTALION OIL CORP received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii)).

“August 19, 2025, Battalion Oil Corporation (the “ Company ”) received a letter (the “ Acceptance Letter ”) from NYSE American LLC (the “ NYSE American ”) notifying the Company that its plan of compliance (the “ Plan ”) has been accepted. The Plan outlines actions the Company intends to take to regain compliance with the continued listing standards of the NYSE American. As previously disclosed, the Company received a notice from NYSE American on May 30, 2025, stating that it was not in compliance with Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide (the “ Company Guide ”)”

AMERICAN REBEL HOLDINGS INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 20, 2025, the Company received written notice from the Listing Qualifications Staff of Nasdaq that the Company has not regained compliance with the Stockholders’ Equity Requirement by August 18, 2025. As a result, unless the Company requests an appeal to a hearings panel (the “Panel”) by August 27, 2025, the Company’s securities will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on August 29, 2025. The Company intends to submit an appeal to Nasdaq on or before August 27, 2025, which will stay the delisting and suspension of th”

Sonder Holdings Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“August 20, 2025, the Company received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the Company is delinquent in filing the Q2 2025 Form 10-Q and remains delinquent in filing the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 (the “Q1 2025 Form 10-Q”), the Company does not comply with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires companies with securities listed on Nasdaq to timely file all required periodic reports with the SEC. The Notice has no immediate effect on the listing or trad”

GRAPHJET TECHNOLOGY received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“August 20, 2025, the Company received a written notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “ Form 10-Q ”) with the U.S. Securities and Exchange Commission. The Notice has no immediate effect on the listing of the Company’s ordinary shares on The Nasdaq Global Market. However, Nasdaq has requested the Company to present its views with respect to this Notice to Nasdaq in wri”

Liminatus Pharma, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“August 22, 2025, Liminatus Pharma, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “Form 10-Q”). The deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on Nasdaq under the symbol “LIMN” at this time. Under the Nasdaq rules, the Company has 60 calendar da”

BROADWAY FINANCIAL CORP \DE\ received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“August 21, 2025, Broadway Financial Corporation (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the periodic financial reporting requirements set forth in Nasdaq Listing Rule 5250(c)(1) (“Rule 5250(c)(1)”) for continued listing on The Nasdaq Capital Market because its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the “Form 10-Q”) was not filed within the time period prescribed by the Securities and Exchange Commission rules. The Notice has no immediate effect on the”

Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“August 20, 2025, the Company received a notice (the “Notification Letter”) from the Nasdaq Listing Qualifications department (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of the Form 10-Q. The notice does not immediately effect the listing or trading of the Company’s securities, which continue to trade on the Nasdaq Capital Market under the symbol “PTIX.” The Company intends to submit a plan to regain compliance within 60 calendar days of the Notification Letter, and Nasdaq may grant an exception of up to 180 calendar day”

STRATA Skin Sciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 19, 2025, Strata Skin Sciences, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). In the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the Company reported stockholders’ equity”

IMMERSION CORP received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“August 20, 2025, Immersion Corporation (the “Company”) received written notice (the “Nasdaq Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it did not timely file its Annual Report on Form 10-K for the fiscal year ended April 30, 2025 (the “Form 10-K”), as required for continued listing on The Nasdaq Stock Market pursuant to Nasdaq Listing Rule 5250(c)(1). Under Nasdaq rules, the Company has 60 calendar days from the date of the Nasdaq Notification Letter to submit to Nasdaq a plan to regain compliance with N”

CURIS INC received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“August 21, 2025, the Company received notice from the Staff stating that, because the Company has not regained compliance with the MVLS Requirement, its securities would be delisted from The Nasdaq Capital Market unless the Company timely appeals the Staff’s delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the “Panel”) by August 28, 2025. The Company intends to make a timely request for a hearing before the Panel to appeal the Staff’s determination. The Company’s request for a hearing will stay the suspension and delisting of the Company’s securities by the Sta”

ModivCare Inc received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“August 20, 2025. In addition, on August 20, 2025, the Company received a notification letter (the “Delinquency Notice”) from Nasdaq notifying the Company that, because the Company is delinquent in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires companies with securities listed on Nasdaq to timely file all required periodic reports with the Securities and Exchange Commission (the “SEC”). Nasdaq informed the Company that the Common Stock would be suspended at the opening of business”

ModivCare Inc received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“August 21, 2025, ModivCare Inc. (the “Company”) received a notification letter (the “Delisting Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq had determined to commence proceedings to delist the Company’s common stock, $0.001 par value per share (the “Common Stock”), from Nasdaq. Nasdaq reached its decision that the Company is no longer suitable for listing pursuant to Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the Company’s commencement of voluntary proceedings under Chapter 11 of the United”

Lyra Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 20, 2025, Lyra Therapeutics, Inc. (the “Company”) received a letter (the “Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “Form 10-Q”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million. As reported on its Form 10-Q, the Company’s stockholders’ equity as of June 30, 2025 was approxim”

BRC Group Holdings, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“August 20, 2025, B. Riley Financial, Inc. (“the Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), which indicated that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”). Nasdaq has granted the Company an exception until September 29, 2025 to file its delinq”

Midland States Bancorp, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“August 19, 2025, the Company received an expected notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that it does not comply with Nasdaq Listing Rule 5250(c)(1) (the “ Listing Rule ”) because of the continued delinquency in filing the Form 10-Q. The Notice has no immediate effect on the listing or trading of the Company’s common stock or depositary shares on the Nasdaq Global Select Market. In accordance with Nasdaq’s listing rules, the Company has until October 18, 2025 to submit to Nasdaq a plan to regain compliance with the Listing Rule. Pursuant to”

GENERATION INCOME PROPERTIES, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 20, 2025, Generation Income Properties, Inc. (the “Company”) received notice (the “Nasdaq Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the Company reported a stockholders’ equity d”

urban-gro, Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1), 5550(b)(1), 9601).

“March 31, 2025 (the “Form 10-Q”) or its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”), the Company continued to be out of compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. On August 18, 2025, the Company received a determination letter (the “Determination”) from Nasdaq stating that Nasdaq had determined that the Company did not file the Form 10-K and the Form 10-Q by August 15, 2025, the date requir”

Corvex, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1), 5550(a)(2)).

“August 21, 2025, Movano Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that because the Company had not yet filed its Form 10-Q for the quarterly period ended June 30, 2025 (the “Form 10-Q”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Filing Requirement”) requiring Nasdaq-listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the “SEC”). The Form 10-Q was due on August 14, 2025. The Company appealed its previous”

ADVENT TECHNOLOGIES HOLDINGS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“d Listing Rule or Standard; Transfer of Listing. As previously disclosed, on October 18, 2024, Advent Technologies Holdings, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) that it was out of compliance with Listing Rule 5550(b)(1), which requires that the Company maintain stockholders’ equity of at least $2,500,000 for continued listing (the “Rule”), or to meet the alternatives of market value of listed securities or net income from continuing operations. The Staff previously granted the Company an exception to reg”

New Fortress Energy Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“August 19, 2025, New Fortress Energy Inc. (the “Company”) received an expected notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) because the Company has not yet filed its Form 10-Q for the period ended June 30, 2025 (“Form 10-Q”) with the U.S. Securities and Exchange Commission (the “SEC”). The Rule requires listed companies to timely file all required periodic financial reports with the SEC. The Notice states that the Company has 60 calendar days”

Triller Group Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“August 19, 2025, the Company received an extension letter (the “Letter”) from Staff, who has granted a further extension of time to enable the Company to file the Delinquent Filings on or before October 13, 2025. The Company is working diligently to complete the Delinquent Filings and expects to meet the Nasdaq filing requirements.”

Beneficient received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 17, 2025, the Company received a letter (the “January 2025 Notice”) from Nasdaq stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) because the bid price for the Company’s Class A common stock had closed below the $1.00 per share minimum threshold required for continued listing on The Nasdaq Capital Market for the previous 30 consecutive business days. The January 2025 Notice provided the Company a 180-calendar day period to regain compliance with the Bid Price Requirement, through July 14, 2025. As also previously disclosed”

Beneficient received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“August 18, 2025, Beneficient (the “Company”) was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 with the Securities and Exchange Commission (the “SEC”), the Company was in non-compliance with the periodic reporting requirement set forth in Nasdaq Listing Rule 5250(c)(1) (the “Filing Requirement”), which could also serve as a separate and additional basis for delisting in addition to the issues described below (such letter, the “Additional”

Spire Global, Inc. received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

“August 20, 2025, Spire Global, Inc. (the “Company”) received written notice from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with the NYSE’s continued listing standards as set forth in Section 802.01E of the NYSE Listed Company Manual due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”) prior to August 19, 2025, the end of the extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amended. Under”

VSEE HEALTH, INC. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“August 20, 2025, the Company received an additional notice from the Staff that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The Company intends to address all late filings before the Panel at the scheduled hearing. While the Company pursues those processes, trading in the Company’s common stock and public warrants will be suspended on Nasdaq after August 28, 2025, unless the Panel grants an additional extension. As a result of the suspension in tradi”

VSEE HEALTH, INC. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“mpany’s filing of an appeal with the Nasdaq Hearings Panel (the “Panel”). A hearing before the Panel is scheduled to be held on September 9, 2025. The Staff’s determination to deny the Company’s request to continue listing on Nasdaq was based on the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file with the Securities and Exchange Commission (the “SEC”) its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the period ended March 31, 2025. On August 20, 2025, the Company”

CN Healthy Food Tech Group Corp. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

“August 20, 2025, Iron Horse Acquisitions Corp. (the “Company”), received a letter (the “MVLS Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days prior to the date of the MVLS Notice, the Company’s Minimum Value of Listed Securities (“MVLS”) was less than $50.0 million, which does not meet the requirement for continued listing on The Nasdaq Global Market, as required by Nasdaq Listing Rule 5450(b)(2)(A)) (the “MVLS Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)”

dMY Squared Technology Group, Inc. received a nyse_american deficiency notice notice regarding late filing (rules 1007).

“August 20, 2025, the Company received a notice (the “Notice”) from the NYSE Regulation staff of the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with Section 1007 of the NYSE American Company Guide (the “Rule”) because it has not timely filed its Second Quarter 10-Q with the SEC. The Rule requires listed companies to timely file all required periodic financial reports with the SEC. The Notice has no immediate effect on the listing or trading of the Company’s securities. However, if the Company fails to timely regain compliance with the Rule, the Company”

High Roller Technologies, Inc. received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(ii)).

“August 19, 2025, High Roller Technologies, Inc. (the “Company”) received notice from the NYSE American LLC (“NYSE American”) that it had accepted the Company’s plan to regain compliance with the NYSE American continued listing standards and granted a plan period through December 4, 2026 (“Plan Period Deadline”). As previously disclosed on June 6, 2025, the Company received a letter from the NYSE American stating that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) of the NYSE American Company Guide, which require stockholders’ equity of”

Rain Enhancement Technologies Holdco, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C), 5810(c)(3)(D)).

“August 19, 2025, the Company received a notice (the “Notice”) from the Staff indicating that the Company had not regained compliance with either the MVLS Rule or the MVPHS Rule and, unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”), the Company’s securities would be subject to suspension and delisting from The Nasdaq Global Market at the opening of business on August 28, 2025. The Company submitted its timely request for a hearing before the Panel on August 21, 2025, to request additional time to regain compliance with the MVLS Rule and the MVPHS Rule.”

ATOSSA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 21, 2025, Atossa Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company’s initial compliance period ended on August 20, 2025, and the Company subsequently requested an extension. On August 21, 2025, the Company was inf”

Nutex Health Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“August 20, 2025, the Company received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “June 30, 2025 Form 10-Q”), with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires the timely filing of all required periodic reports with the SEC. Under Nasdaq r”

DevvStream Corp. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(A)(ii)).

“mpliance because the Company does not comply with any of the stockholders’ equity initial listing requirements of the Nasdaq Capital Market and thus does not comply with the applicable initial listing requirements that the Company must meet to qualify for a second grace period as per Listing Rule 5810(c)(3)(A)(ii). Accordingly, unless the Company submits an appeal of the delisting determination to Nasdaq by no later than 4:00 p.m. Eastern Time on August 22, 2025(the “ Appeal Deadline ”), Nasdaq has informed the Company that its Common Shares will be scheduled for delisting from The Nasdaq C”

Genprex, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 19, 2025, Genprex, Inc. (“Genprex” or the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”), because the Company’s stockholders’ equity of $1,391,195 as reported in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2025 was below the required minimum of $2.5 millio”

WINDTREE THERAPEUTICS INC /DE/ received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“August 19, 2025, Windtree Therapeutics Inc. (the “ Company ” ) was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as a result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(a)(2), Nasdaq has determined to delist the Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock effective at the open of trading on August 21, 2025. The Company expects that its common stock will begin trading publicly on the over-the-counter market on August 21, 2025, under its existing symbol “WINT.” The Com”

HCW Biologics Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 19, 2025, the Company received written notice from the Staff that as of June 30, 2025, the Company was non-compliant with the Equity Rule, so its securities would be suspended from trading on Nasdaq on August 28, 2025 unless it requests a hearing by August 26, 2025. The Company plans to timely request a hearing before the Panel, which will stay the suspension of trading of the Company's securities on Nasdaq pending completion of the hearing process. The Company is considering all options available to it to regain compliance with the Equity Rule; however, there can be no assurance that t”

HCW Biologics Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“June 26, 2025, HCW Biologics Inc. (the “Company”) announced that it received formal notice from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) that the Company was in compliance with Listing Rule 5550(b)(1) (the “Equity Rule”) for continued listing of its securities on the Nasdaq Capital Market tier. The Company was also notified that it will remain subject to a “Panel Monitor,” as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year from the date of the Nasdaq notice, through June 23, 2026. If, during the term of the Pan”

FOXO TECHNOLOGIES INC. received a nyse_american delisting notice notice regarding minimum bid price (rules 1003(f)(v)).

“August 12, 2025, FOXO Technologies Inc., a Delaware corporation (the “ Company ”), received a letter from NYSE confirming that NYSE Regulation has determined to commence proceedings to delist the Class A Common Stock of the Company from NYSE American, pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Class A Common Stock. The share price went below the NYSE minimum price of $0.10 on August 12, 2025 and was immediately suspended from trading by NYSE. The Company submitted an application to have its common stock traded on the OTC and has on Aug”

TPI COMPOSITES, INC received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“August 12, 2025, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Nasdaq Staff has determined that the Company’s common stock, par value $0.01 per share (the “Common Stock”) will be delisted from the Nasdaq in accordance with Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the Company’s commencement of the Chapter 11 Cases.. The Company does not intend to appeal this determination. Trading of the Company’s Common Stock will be suspended at the opening of business on August 19, 2025, and a”

AMC Global Media Inc. received a nasdaq noncompliance notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4), 5605(c)(4)(B)).

“August 14, 2025, the Company received a notice letter from Nasdaq acknowledging that, as a result of Dr. Tow’s death on August 10, 2025, the Company is no longer in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires the Board’s Audit Committee to be composed of at least three “independent directors” (as defined in Nasdaq Listing Rule 5605(a)(2)). The Nasdaq letter further provided that, pursuant to Nasdaq Listing Rule 5605(c)(4), the Company is entitled to a cure period to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A), which cure period will expire upon the earlier of”

SmartKem, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 15, 2025, SmartKem, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company’s stockholders’ deficit of ($127,000) as reported in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2025 was below the required minimum of $2.5 million, and because, as of August 15, 2025, the Company did”

FGI Industries Ltd. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“August 14, 2025, FGI Industries Ltd. (the “Company”) received written confirmation from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). Consequently, the Company is now in compliance with all applicable listing standards and will continue to be listed on the Nasdaq Capital Market. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly”

SOLIGENIX, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 15, 2025, Soligenix, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). In the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the Company reported stockholders’ equity of $1,828,951”

DNA X, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“August 13, 2025, Sonim Technologies, Inc. (the “Company”) received a letter (the “Notice”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) for continued listing. The Bid Price Rule requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”) provides that a failure to meet the minimum bid price requirement ex”